NeuroSense Therapeutics Ltd.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−10.21 M USD
0.00 USD
23.30 M
About NeuroSense Therapeutics Ltd.
Sector
Industry
CEO
Alon Ben-Noon
Website
Headquarters
Herzliya
Founded
2017
Identifiers
2
ISIN IL0011811630
Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.
Displays a symbol's price movements over previous years to identify recurring trends.